Delta 9 Cannabis - CEO, John Arbuthnot.
CEO, John Arbuthnot.
Source: Delta 9 Cannabis.
  • Delta 9 (DN) has announced a binding commitment letter for a C$32M non-dilutive credit facility
  • The facility, with connectFirst Credit Union, includes a $23M commercial mortgage facility, a $5M acquisition facility and a $4M authorized overdraft
  • The company will use the proceeds for debt repayments, general working capital and continued growth through the acquisition of EBITDA-positive Canadian cannabis businesses
  • Delta 9 Cannabis is a vertically integrated cannabis company
  • Delta 9 (DN) is unchanged trading at $0.295 per share

Delta 9 (DN) has announced a binding commitment letter for a C$32M non-dilutive credit facility.

The facility, with connectFirst Credit Union, includes a $23M commercial mortgage facility, a $5M acquisition facility and a $4M authorized overdraft.

The mortgage facility matures after five years, amortizes over a 12-year term and will be put toward the following purposes:

  • $11.2M for the repayment of existing long-term debt
  • $11.8 million for the repayment of Delta’s 8.5-per-cent unsecured convertible debentures due July 17, 2022

The company will pay a five-year fixed rate of 4.55 per cent per year on the mortgage facility and connectFirst prime + 1.50 per cent per year for the authorized overdraft.

The credit facilities will result in $1.2M in operating capital on closing and $470,000 in annualized principal repayment reductions.

Besides debt repayments, it will allocate the proceeds toward general working capital and continued growth through the acquisition of EBITDA-positive Canadian cannabis businesses.

“With this debt financing, Delta 9 has added financial flexibility to optimize its capital structure and is well-positioned to continue to execute its growth strategy,” said John Arbuthnot, CEO of Delta 9.

Delta 9 Cannabis is a vertically integrated cannabis company.

Delta 9 (DN) is unchanged trading at $0.295 per share as of 11:51 am EST.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.